JAK Inhibitors for Crohn's Disease: A Systematic Review and Dose-Response Network Meta-Analysis of Efficacy and Safety.

JGH Open · 2026 · PMC13097650 · PMID 42022940

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Upadacitinib 6 mg BID showed the highest relative efficacy (RR: 2.7, 95% CrI: 0.69–11.0), followed by 24 mg BID (RR: 2.2, 95% CrI: 0.56–9.5), but these differences did not reach statistical significance (Figure 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.